Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer.
anatomic stage
inflammatory breast cancer
prognostic stage
staging
the American Joint Committee on Cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Oct 2020
24 Oct 2020
Historique:
received:
06
09
2020
revised:
15
10
2020
accepted:
18
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
The AJCC updated its breast cancer staging system to incorporate biological factors in the "prognostic stage". We undertook this study to validate the prognostic and anatomic stages for inflammatory breast cancer (IBC). We established two cohorts of IBC diagnosed without distant metastasis: (1) patients treated at The University of Texas MD Anderson Cancer Center between 1991 and 2017 (MDA cohort) and (2) patients registered in the national Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 (SEER cohort). For prognostic staging, estrogen receptor (ER)+/progesterone receptor (PR)+/ human epidermal growth factor receptor-2 (HER2)+/grade 1-2 was staged as IIIA; ER+/PR-/HER2-/grade 3, ER-/PR+/HER2-/grade 3, and triple-negative cancers as IIIC; and all others as IIIB. Endpoints were breast cancer-specific survival (BCSS), overall survival (OS), and disease-free survival (DFS). We studied 885 patients in the MDA cohort and 338 in the SEER cohort. In the MDA cohort, the prognostic stage showed significant predictive power for BCSS, OS, and DFS (all
Identifiants
pubmed: 33114311
pii: cancers12113105
doi: 10.3390/cancers12113105
pmc: PMC7690918
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Oncotarget. 2017 Jul 25;8(30):49370-49379
pubmed: 28472761
J Clin Oncol. 2014 Jul 1;32(19):2018-24
pubmed: 24888808
Future Oncol. 2019 Feb;15(5):507-516
pubmed: 30378451
JAMA Oncol. 2018 Feb 1;4(2):203-209
pubmed: 29222540
Saudi Med J. 2014 Nov;35(11):1324-30
pubmed: 25399208
Eur J Breast Health. 2018 Oct 01;14(4):211-217
pubmed: 30288495
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
Oncologist. 2011;16(12):1675-83
pubmed: 22147002
Clin Breast Cancer. 2018 Feb;18(1):1-8
pubmed: 28712925
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Breast. 2018 Feb;37:56-63
pubmed: 29100045
Oncologist. 2007 Aug;12(8):904-12
pubmed: 17766649
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Anticancer Res. 2017 Aug;37(8):4615-4621
pubmed: 28739761
Breast Cancer Res Treat. 2018 Feb;168(1):269-275
pubmed: 29143220
Ann Oncol. 2011 Mar;22(3):515-523
pubmed: 20603440
Ann Oncol. 2014 Feb;25(2):384-91
pubmed: 24351399